ID.1
Item
diagnosed with type 2 diabetes.
boolean
C0011860 (UMLS CUI [1])
ID.2
Item
treated with metformin and/or a thiazolidinedione.
boolean
C0025598 (UMLS CUI [1,1])
C1257987 (UMLS CUI [1,2])
ID.3
Item
hba1c between 6.5% and 9.5%, inclusive.
boolean
ID.4
Item
body mass index (bmi) > 25 kg/m^2 and < 40 kg/m^2.
boolean
C1305855 (UMLS CUI [1])
ID.5
Item
have previously received exenatide or glucagon-like peptide-1 analogs.
boolean
C0167117 (UMLS CUI [1,1])
C0061355 (UMLS CUI [1,2])
ID.6
Item
have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of screening. this criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.
boolean
C2348577 (UMLS CUI [1])
ID.7
Item
receiving beta blockers.
boolean
C0001645 (UMLS CUI [1])
ID.8
Item
receiving treatment with a drug directly affecting gastrointestinal motility, including but not limited to reglan® (metoclopramide), propulsid® (cisapride), and chronic macrolide antibiotics.
boolean
C0017184 (UMLS CUI [1,1])
C0722861 (UMLS CUI [1,2])
C0034977 (UMLS CUI [1,3])
C0003240 (UMLS CUI [1,4])
ID.9
Item
have received treatment with systemic glucocorticoid therapy by oral, intravenous (iv), or intramuscular (im) route within 6 weeks of screening, or are regularly treated with potent, inhaled intranasal steroids that are known to have a high rate of systemic absorption or bronchodilators.
boolean
C0017710 (UMLS CUI [1])
ID.10
Item
have been treated with drugs that promote weight loss (for example, adipex®
boolean
C0376606 (UMLS CUI [1])
ID.11
Item
[phentermine], acomplia® [rimonabant], xenical® [orlistat], meridia® [sibutramine], acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening.
boolean
C0031447 (UMLS CUI [1,1])
C1142933 (UMLS CUI [1,2])
C0076275 (UMLS CUI [1,3])
C0074493 (UMLS CUI [1,4])
C0031495 (UMLS CUI [1,5])
ID.12
Item
have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to screening: *insulin; *alpha-glucosidase inhibitors (for example, glyset® [miglitol] or precose® [acarbose]); *meglitinides (for example, prandin® [repaglinide] or starlix® [nateglinide]); *sulfonylureas (for example, glucotrol® [glipizide] or micronase® [glyburide]); *dipeptidyl peptidase iv (dpp-iv) inhibitors (for example, januvia™ [sitagliptin])
boolean
C0021641 (UMLS CUI [1,1])
C1299007 (UMLS CUI [1,2])
C0065880 (UMLS CUI [1,3])
C0038766 (UMLS CUI [1,4])
C0081937 (UMLS CUI [1,5])
ID.13
Item
have donated blood within 60 days of screening.
boolean
C0005795 (UMLS CUI [1])